GORE VSX 20-03 – Evaluation of the use of the “GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface” (VSX), a device manufactured by W. L. Gore & Associates, Inc. (“Device”)

ZEISS – Certifications and Foundations of Safe Machine Learning Systems in Healthcare

Refernzkundenvertrag – Siemens Refernzkundenvertrag

SCHI 498/11-2

Melanom – Ein Ganzkörper Radiomics ansatz zur Outcome-Vorhersage in Patienten mit metastasiertem Melanom unter Systemtherapie

Age – Bestimmung des organ-spezifischen biologischen Alters anhand von Ganzkörper MRT-Daten aus der NAKO MR Studie

Muscle – Bildmorphologische Biomarker der menschlichen Skelettmuskulatur (Muskelmasse, morphologische und Textureigenschaften von Muskelgruppen desKörperstamms, Oberschenkels und Oberarms) bei Sarkopenie und kardiometabolischen Erkrankungen

Melanom – Ein Ganzkörper Radiomics Ansatz zur Outcome-Vorhersage in Patienten mit metastasiertem Melanom unter Systemtherapie

DFG 1042/2-1 – “Numerische Multiphysikmodellierung des postprandialen menschlichen Magens“

PET-LIT – Metastasierte Melanompatienten unter Immuntherapie: Überwachung des Therapieerfolges mittels Liquid Biopsy und PET/CT im Rahmeneiner prospektiven Studie (PET-LIT)

Euroscreen ESN 364 – A Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Uterine Fibroids

monarcHER – A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician’s Choice plus Trastuzumab in Women with HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive, HER2 Negative Breast Cancer

D419LC00001 – A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients

A Phase III, open-label, randomized Study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma

HIP – Automated segmentation and quantification of geometrical and structural parameters of the hip in 3D-MRI data sets – Development of algorithms for reliable data analysis in large cohorts (German National Cohort)

"Charakterisierung unbewusster spontaner fokaler Muskelaktivität mittels bewegungssensitiver Magnetresonanz-Bildgebung und automatischer Datennachverarbeitung"

MultiscaleHCC: Diagnose und Therapie des hepatozellulären Karzinoms (HCC) unter Einbeziehung von Omics-Methoden (Metabolomics, Proteomics), der multiparametrischen Bildgebung und Methoden der Systemmodellierung

Periinterventionelle 3D-Bildgebung

A randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of the Bruton’s Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma

ALTERNATIVE: a prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Evaluation of the Gynesonics System for Transcervical Treatment of Symptomatic Uterine Fibroids with Radiofrequency Ablation under Integrated Intrauterine Sonography Guidance

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer

A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer

Zusammenarbeit auf dem Gebiet der CT Bildgebung am SOMATOM Force.

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma

D4198C00001 – A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 1b Study to Assess the Safety and Anti-tumour Activity of Dexanabinol Monotherapy and Dexanabinol in Combination with Chemotherapy in Patients with Advanced Tumours

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN NAB-PACLITAXEL FOR CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON SMALL CELL LUNG CANCER

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma

Phase I/II-Studie zu MK-3475 (Pembrolizumab) bei Kindern mit fortgeschrittenem Melanom oder einem PD-L1 positiven fortgeschrittenen, rezidivierten oder therapierefraktären solidem Tumor oder Lymphom, bei der die Pharmakokinetik, Pharmakodynamik, Toxizität, Sicherheit und antitumorale Aktivität von MK-3475 untersucht werden

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK- 3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group

A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Studie MK-3475 -185

A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE-119)

A randomised, double blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in newly diagnosed patients with inoperable locally advanced NSCLC after definitive concurrent chemoradiation therapy

A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0810 VERSUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC ER /HER2  BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY